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diverse cancer model systems to 
examine the safety and effective-
ness of NF-κB therapeutics. In that 
regard, computational modeling may 
prove useful in integrating the com-
plexity of cell-intrinsic and intercellu-
lar molecular mechanisms, tonic and 
responsive signaling, and pharma-
cokinetics and drug metabolism to 
predict or evaluate the effectiveness 
of therapeutic agents.
RefeRences
Basak, S., Kim, H., Kearns, J.D., Tergaonkar, 
V., O’Dea, E., Werner, S.L., Benedict, C.A., 
Ware, C.F., Ghosh, G., Verma, I.M., and Hoff-
mann, A. (2007). Cell 128, 369–381.
Gapuzan, M.E., Schmah, O., Pollock, A.D., 
Hoffmann, A., and Gilmore, T.D. (2005). Onco-
gene 24, 6574–6583.
Greten, F.R., Eckmann, L., Greten, T.F., Park, 
J.M., Li, Z.W., Egan, L.J., Kagnoff, M.F., and 
Karin, M. (2004). Cell 118, 285–296.
Hoffmann, A., and Baltimore, D. (2006). Immu-
nol. Rev. 210, 171–186.
Lavon, I., Goldberg, I., Amit, S., Landsman, 
L., Jung, S., Tsuberi, B.Z., Barshack, I., Kopo-
lovic, J., Galun, E., Bujard, H., and Ben-Neriah, 
Y. (2000). Nat. Med. 6, 573–577.
Li, Q., and Verma, I.M. (2002). Nat. Rev. Im-
munol. 2, 725–734.
Luedde, T., Beraza, N., Kotsikoris, V., van Loo, 
G., Nenci, A., De Vos, R., Roskams, T., Traut-
wein, C., and Pasparakis, M. (2007). Cancer 
Cell, this issue.
Maeda, S., Kamata, H., Luo, J.L., Leffert, H., 
and Karin, M. (2005). Cell 121, 977–990.
Pikarsky, E., Porat, R.M., Stein, I., Abramov-
itch, R., Amit, S., Kasem, S., Gutkovich-Pyest, 
E., Urieli-Shoval, S., Galun, E., and Ben-Neri-
ah, Y. (2004). Nature 431, 461–466.
Sakurai, T., Maeda, S., Chang, L., and Karin, 
M. (2006). Proc. Natl. Acad. Sci. USA 103, 
10544–10551.
Schmidt-Ullrich, R., Aebischer, T., Hulsken, J., 
Birchmeier, W., Klemm, U., and Scheidereit, C. 
(2001). Development 128, 3843–3853.
van Hogerlinden, M., Rozell, B.L., Ahrlund-
Richter, L., and Toftgard, R. (1999). Cancer 
Res. 59, 3299–3303.
Zhang, J.Y., Green, C.L., Tao, S., and Khavari, 
P.A. (2004). Genes Dev. 18, 17–22.A Radical Role for p38 MAPK in Tumor Initiation
Norman J. Kennedy,1 Cristina Cellurale,1 and Roger J. Davis1,2,*
1Program in Molecular Medicine, University of Massachusetts Medical School
2Howard Hughes Medical Institute
Worcester, MA 01605, USA
*Correspondence: roger.davis@umassmed.edu
DOI 10.1016/j.ccr.2007.01.009
It is established that p38 MAPK can negatively regulate tumorigenesis, but the mechanism is incom-
pletely understood. A new study in this issue of Cancer Cell shows that p38 MAP kinase plays a 
selective role in tumor initiation mediated by oxidative stress.Cells sense changes in their environ-
ment by activating signal transduc-
tion pathways that direct biochemical 
programs to mediate proliferation, 
differentiation, and survival. The mito-
gen-activated protein kinase (MAPK) 
family represents an important group 
of signaling proteins that can regulate 
these fundamental cellular processes. 
The extracellular signal-regulated 
kinase (ERK) MAPK pathway primarily 
directs a program of proliferation and 
survival, while the cJun NH2-terminal 
kinase (JNK) pathway can promote 
either proliferation or apoptosis (Ken-
nedy and Davis, 2003). Conversely, the 
p38 MAPK pathway is activated upon 
cellular stress and often engages path-
ways that can block proliferation or 
promote apoptosis (Bulavin and For-
nace, 2004).The importance of MAPK pathways 
to cell proliferation and death is high-
lighted by the observation that dysreg-
ulation of these kinase cascades can 
result in cell transformation and can-
cer. Activated ERK and JNK pathways 
can lead to increased proliferation and 
survival, although loss of JNK in some 
instances may also promote tumori-
genesis (Kennedy and Davis, 2003). 
In contrast, the p38 MAPK pathway is 
implicated in suppression of tumorigen-
esis because it can inhibit cell growth 
by decreasing the expression of cyclin 
D (Lavoie et al., 1996), inhibit the activ-
ity of Cdc25 phosphatases (Manke et 
al., 2005), and engage the p16/Rb and 
p19ARF/p53 tumor suppressor pathways 
(Bulavin et al., 2002, 2004). The p38 
MAPK pathway can also cause apop-
tosis by a mechanism that is incom-Cancer Cell 11pletely understood but may involve 
the phosphorylation of members of 
the Bcl2 family and activation of the 
mitochondrial apoptotic pathway (Fig-
ure 1). The selectivity of the p38 MAPK 
signaling pathway in tumor suppres-
sion is unclear. However, a new study 
by Dolado et al. (2007) reported in this 
issue of Cancer Cell now demonstrates 
that p38 MAPK selectively functions as 
a sensor of oxidative stress during the 
initiation of tumorigenesis.
Dolado et al. examined the proper-
ties of fibroblasts isolated from p38α−/− 
mice when transformed by an acti-
vated HRasV12 oncogene. They report 
that p38α deficiency caused increased 
proliferation, an increased number of 
foci, an increased ability to form colo-
nies in soft agar, and decreased apop-
tosis. The p38α-deficient cells also , February 2007 ©2007 Elsevier Inc. 101
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Previewsfigure 1. schematic Illustration of the effects of Reactive Oxygen species on the 
p38 MAP Kinase signal Transduction Pathway
ROS, reactive oxygen species.formed subcutaneous tumors more 
rapidly than wild-type cells. Impor-
tantly, these effects of p38α deficiency 
were rescued by ectopic expression 
of p38 MAPK. Together, these data 
suggest that p38 MAPK acts to sup-
press tumor formation by HRas and 
lend strong support to the conclusions 
derived from previous studies that 
the p38 MAPK pathway contributes 
to tumor suppression (Brancho et al., 
2003; Bulavin et al., 2002; Chen et al., 
2000).
Dolado et al. show that the effects of 
p38α deficiency on HRas-stimulated 
transformation are mediated by reactive 
oxygen species (ROS). HRas is known 
to cause an increase in ROS production 
(Irani et al., 1997). Interestingly, trans-
formed p38α-deficient cells accumu-
late much larger amounts of ROS than 
wild-type cells. Dolado et al. report that 
ROS-stimulated p38 MAPK activity 
acts to induce apoptosis in wild-type 
cells and that p38α-deficient cells are 
resistant to ROS-induced apoptosis. 
Pharmacological studies indicated that 
the source of ROS was from NADPH 
oxidases rather than mitochondria. 
Indeed, increased expression of NOX1 
and NOX4 was detected in p38α-defi-
cient cells. Dolado et al. propose that 
the increased accumulation of ROS in 
p38α-deficient cells contributes to the 
transformed phenotype because of the 102 Cancer Cell 11, February 2007 ©2007ability of ROS to induce genetic insta-
bility. The observation that the addition 
of an antioxidant to p38α-deficient cells 
can suppress their transformed pheno-
type is consistent with this conclusion.
How do ROS lead to the activation 
of the p38 MAPK pathway? Dolado et 
al. suggest that the activation of p38 
MAPK is mediated by the MAPK kinase 
kinase ASK1. This protein kinase is 
activated by oligomerization and phos-
phorylation. However, in nonstressed 
cells, these processes are inhibited 
by the interaction of ASK1 with Thio-
redoxin (Trx) and Glutathione S-trans-
ferase µ (GSTm) proteins. Following 
ROS-mediated stress, the Trx and 
GSTm proteins dissociate from ASK1 
in a manner that may involve oxidation 
of cysteine residues critical for these 
interactions. ASK1 can then activate 
the p38 MAPK pathway by phosphory-
lating and activating the MAPK kinases 
MKK3, MKK4, and MKK6 (Brancho et 
al., 2003). Therefore, Trx and GSTm 
proteins may act as ROS sentinels that 
are triggered by oxidation to activate 
stress MAPK pathways in response to 
oncogenic transformation (Figure 1).
ROS can also employ another tactic 
to activate MAPK pathways—the inacti-
vation of phosphatases. The best-char-
acterized example of ROS-mediated 
inactivation of a phosphatase is pro-
vided by structural analysis of PTP1B,  Elsevier Inc.which is inhibited by the reversible 
ROS-mediated oxidation of an active 
site cysteine residue. ROS may similarly 
modify a number of other phospha-
tases that inhibit the p38 MAPK path-
way, including PP2Cε and PP5, which 
inactivate ASK1; PP2Cα, which inacti-
vates MAPK kinases; and MAPK phos-
phatases (MKP) and WIP1/PPM1D, 
which inactivate p38 MAPK (Figure 1). 
Thus, the effect of ROS to activate the 
ASK1/p38 pathway is potentiated by 
the effect of ROS to inhibit phospha-
tases that inactivate the p38 MAPK 
pathway. A direct demonstration that 
ROS-mediated phosphatase inhibi-
tion contributes to p38 MAPK activa-
tion is required. Nevertheless, genetic 
analysis has confirmed that loss of p38 
MAPK phosphatase function can mod-
ulate tumorigenesis. Thus, deficiency 
of the p38 MAPK phosphatase WIP1/
PPM1D suppresses transformation 
caused by HRas (Bulavin et al., 2002). 
Moreover, WIP1-deficient mice display 
a delay in mammary tumorigenesis 
that was dependent on increased p38 
MAPK activity (Bulavin et al., 2004). 
Interestingly, WIP1-deficient cells are 
unable to form tumors because of 
increased p38 MAPK activity and sub-
sequently increased expression of the 
Cdkn2a tumor suppressor locus that 
encodes p19 ARF/p16Ink4a, but the tumor-
igenic potential of WIP1-deficient cells 
is restored by Cdkn2a deletion (Bulavin 
et al., 2004).
Is ROS-stimulated p38 MAPK acti-
vation relevant to human cancer? p38 
MAPK appears to protect against 
oncogenes that produce high levels of 
ROS. In this regard, Dolado et al. dem-
onstrate that high levels of ROS were 
induced by some oncogenes (e.g., 
HRas, NRas, and Neu), and this result 
correlated with increased transfor-
mation of p38α-deficient fibroblasts. 
The suggestion that p38 MAPK may 
protect against ROS-stimulated trans-
formation may therefore have clinical 
significance. The importance of the 
p38 MAPK pathway to cancer is further 
reflected by the observation that muta-
tion or overexpression of genes that 
regulate p38 MAPK activity are found 
in human tumors. For example, WIP1/
PPM1D is an oncogene that is overex-
pressed in mammary tumors (Bulavin 
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Previewset al., 2002). No mutations in p38α 
have been reported in primary tumors; 
the presence of three other p38 MAPK 
genes could compensate for any par-
tial loss of function of p38α.
The successful creation of a tumor 
requires that the apoptotic and antip-
roliferative effects of p38 MAPK must 
be suppressed. Dolado et al. propose 
that one mechanism employed by 
tumor cells to overcome the tumor-
suppressive function of p38 MAPK is to 
uncouple the production of ROS from 
p38 MAPK activation. The increased 
expression of GSTm proteins (Gstm1 
and GSTm2) observed in tumor cells 
may serve this function. Dolado et 
al. show that reduced expression of 
GSTm2 in MCF7 breast cancer cells 
increased p38 MAPK activity and 
apoptosis, whereas forced overex-
pression of GSTm2 further potentiated 
the transformed phenotype. Since Fanconi anemia (FA) is a recessive syn-
drome characterized by chromosomal 
instability, congenital malformations, 
progressive bone marrow failure, and 
hypersensitivity to DNA crosslink-
ing agents (Taniguchi and D’Andrea, 
2006). The genes responsible for 11 of 
the 12 FA complementation groups (A, 
B, C, D1, D2, E, F, G, I, J, L, and M) have 
been identified. Eight FA proteins form 
a complex that activates FANCD2 via 
monoubiquitination (Figure 1). Monou-
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p38 pathway, these data are compel-
ling. However, it is unclear if the over-
expression of GSTm proteins in these 
cancer cells is a cause of or a result of 
transformation or if the increased levels 
reflect responses to tumor treatment or 
passage in tissue culture. Neverthe-
less, proteins that serve as sensors for 
ROS levels (e.g., GSTm1/2) and other 
proteins that attenuate the p38 MAPK 
pathway (e.g., WIP1) represent candi-
date drug targets for the design of new 
therapies for cancer.
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Biallelic mutations in PALB2, the 
“partner and localizer of BRCA2,” are 
responsible for a new FA complemen-
tation group, FA-N (Xia et al., 2006a; 
Reid et al., 2006). PALB2 was originally 
identified in a screen for proteins pres-
ent in complexes containing BRCA2 
(Xia et al., 2006b). PALB2 binds to the 
extreme N terminus of BRCA2 and sta-
bilizes BRCA2 in key nuclear structures, 
allowing it to function in DNA repair and 
at the S phase checkpoint. Decrease of 
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